Richard, Muriel http://orcid.org/0000-0003-0295-7730
Kaufmann, Priska http://orcid.org/0000-0003-2415-3012
Ort, Marion http://orcid.org/0000-0002-9308-5853
Kornberger, RĂ¼diger
Dingemanse, Jasper http://orcid.org/0000-0002-4083-5817
Clinical trials referenced in this document:
Documents that mention this clinical trial
Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug
https://doi.org/10.1007/s40263-019-00697-1
Funding for this research was provided by:
Actelion Pharmaceuticals (AC-083-102)
Idorsia Pharmaceuticals (AC-083-102)
Article History
First Online: 28 January 2020
Compliance with Ethical Standards
:
: This work was supported by Actelion Pharmaceuticals Ltd, the predecessor of Idorsia Pharmaceuticals Ltd, and Idorsia Pharmaceuticals Ltd.
: At the time of study conduct, Muriel Richard, Priska Kaufmann, and Jasper Dingemanse were employees at Actelion Pharmaceuticals Ltd (predecessor of Idorsia Pharmaceuticals Ltd) and Idorsia Pharmaceuticals Ltd. Marion Ort was an employee at Idorsia Pharmaceuticals Ltd. RĂ¼diger Kornberger was an investigator of this study that was funded by Actelion Pharmaceuticals Ltd and Idorsia Pharmaceuticals Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the article.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (ethics committee of Berlin) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: All subjects gave written informed consent prior to any study-mandated procedure.